Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TC-110 in R/R NHL or ALL
NCT04323657Phase 2Completed
- Sponsor
- TCR2 Therapeutics Inc.
- Start
- Mar 2020
- Primary completion
- Feb 2023
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD19 ε-TRuC in non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), mantle cell lymphoma (MCL), sponsored by TCR2 Therapeutics Inc.. Started Mar 2020; status: completed.
02
Drugs
CD19 ε-TRuC
03
Conditions
non-Hodgkin lymphoma (NHL)acute lymphoblastic leukemia (ALL)diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04323657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04323657.